Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Implants / Devices
    • Medtronic unveils...

    Medtronic unveils VenaSeal Closure System in India to treat patients with CVD

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 27 July 2019 3:45 AM  |  Updated On 27 July 2019 3:45 AM
    Medtronic unveils VenaSeal Closure System in India to treat patients with CVD

    Mumbai: India Medtronic Private Limited, wholly-owned subsidiary of Medtronic plc, announced the launch of the VenaSeal Closure System, which is a minimally invasive procedure that uses a proprietary medical adhesive to close the diseased vein in patients with a chronic venous disease (CVD) – a condition affecting more than 190 million people globally.


    VenaSeal uses a medical adhesive to close the diseased vein, with high closure rates across three clinical trials. Using ultrasound, the physician guides a catheter through a small access site in the leg and into the diseased area of the vein. Once in place, the physician administers the VenaSeal adhesive at various points in a segmental fashion, and with manual compression, closes the vein. Blood is re-routed through other healthy veins in the leg.


    This unique approach eliminates the risk of burning or nerve injury that is sometimes associated with thermal-based procedures. The procedure is administered without the use of tumescent anesthesia (multiple injections of a dilute local anesthetic), minimizing the need for multiple needle sticks. In the VeClose trial, patients reported minimal to no pain or bruising, post-procedure.


    Commenting on the launch, Madan Krishnan, vice president, and managing director, India Medtronic Pvt Ltd said, “Medtronic is committed to developing smart product and procedural solutions in the area of minimally invasive innovation to improve the quality of life for all patients."


    “VenaSeal is an innovative approach to vein closure and is designed to minimize patient discomfort and reduce recovery time.2-5 Thousands of patients around the world have benefited from this therapy and we are pleased to now offer this advanced technology in India,” Krishnan added.


    Healthy leg veins have valves that keep blood flowing to the heart. Venous reflux disease, also known as CVD, develops when the valves stop working properly and allow blood to flow backward (i.e., reflux) and pool in the lower leg veins. If CVD is left untreated, symptoms can worsen over time.


    Read Also: USFDA Warning: Medtronic recalls insulin pumps over cybersecurity vulnerabilities

    anesthesiachronic venous diseaseCVDIndia MedtronicMadan Krishnanmedical adhesivemedical deviceMedtronicMedtronic launchpharmapharma newspharma news indiaUltrasoundVeCloseVenaSealVenaSeal Closure SystemVenous reflux disease

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok